Evidence map›Paper›PMID 38898947›Full record

ArticleACS pharmacology & translational science2024

Immunofilaments Are Well Tolerated after Local or Systemic Administration in Mice.

Lea Weiss, René Classens, Marjolein Schluck, Emilia Grad, Yusuf Dölen, Lieke van der Woude, Dominique van Midden, Lisa Maassen, Kiek Verrijp, Koen van Riessen and 4 more

Abstract read
In one paragraph

Article in ACS pharmacology & translational science, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Lea WeissDepartment of Medical BioSciences, Radboudumc, Geert Grooteplein 26, Nijmegen, GA 6525, The Netherlands.
René ClassensDepartment of Medical BioSciences, Radboudumc, Geert Grooteplein 26, Nijmegen, GA 6525, The Netherlands.
Marjolein SchluckDepartment of Medical BioSciences, Radboudumc, Geert Grooteplein 26, Nijmegen, GA 6525, The Netherlands.
Emilia GradDepartment of Medical BioSciences, Radboudumc, Geert Grooteplein 26, Nijmegen, GA 6525, The Netherlands.
Yusuf DölenDivision of Immunotherapy, Oncode Institute, Radboud University Medical Center, Nijmegen, GA 6525, The Netherlands.
Lieke van der WoudeDepartment of Pathology, Radboudum, Geert Grooteplein 10, Nijmegen, GA 6525, The Netherlands.
Dominique van MiddenDepartment of Pathology, Radboudum, Geert Grooteplein 10, Nijmegen, GA 6525, The Netherlands.
Lisa MaassenDepartment of Medical BioSciences, Radboudumc, Geert Grooteplein 26, Nijmegen, GA 6525, The Netherlands.
Kiek VerrijpDepartment of Medical BioSciences, Radboudumc, Geert Grooteplein 26, Nijmegen, GA 6525, The Netherlands.
Koen van RiessenDepartment of Medical BioSciences, Radboudumc, Geert Grooteplein 26, Nijmegen, GA 6525, The Netherlands.
Eric van DintherDepartment of Medical BioSciences, Radboudumc, Geert Grooteplein 26, Nijmegen, GA 6525, The Netherlands.
Philipp M HagemannDepartment of Medical BioSciences, Radboudumc, Geert Grooteplein 26, Nijmegen, GA 6525, The Netherlands.
Carl G FigdorDepartment of Medical BioSciences, Radboudumc, Geert Grooteplein 26, Nijmegen, GA 6525, The Netherlands.
Roel HamminkDepartment of Medical BioSciences, Radboudumc, Geert Grooteplein 26, Nijmegen, GA 6525, The Netherlands.ORCID https://orcid.org/0000-0001-8721-5271

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The invention of nanosized biomaterials has paved the way for novel therapeutics that can manipulate cells on a nanoscale. Nanosized immunofilaments (IFs) are synthetic filamentous polymers consisting out of polyisocyanopeptides, which have been recently established as a powerful platform to activate specific immune cells in vivo such that they raise an antitumor immune response. However, toxicological effects or immunogenicity toward the IFs have not yet been investigated. In this study, we evaluated potential toxic or immunogenic effects in C57BL/6 mice upon intravenous or subcutaneous injection of nonfunctionalized IFs or immunostimulatory IFs over 30 days. We here present a detailed analysis of the gross pathology, hematological parameters, blood biochemistry, histology, and antibody-response against the IF backbone. Our results demonstrate that IFs do not induce severe acute or chronic toxicity in mice. After 30 days, we only found elevated IgG-titers in intravenously injected but not subcutaneously injected mice. In summary, we demonstrate that IFs can be administered into a living organism without adverse side effects, thereby establishing the safety of IFs as a therapeutic intervention.

Identifiers

PMID38898947
PMCPMC11184597

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.